Mallinckrodt
This article was originally published in The Gray Sheet
Executive Summary
Acquires exclusive worldwide rights to expandable intrauterine sensor technology and plans to integrate it into its N-400 fetal pulse oximetry system. Available outside the U.S. since 1995, the firm's Nellcor Perinatal business has completed a multisite, randomized clinical trial of the device in preparation for a PMA submission to FDA